The IDKmonitor® Golimumab Drug Level ELISA is intended to quantitatively determine free golimumab (therapeutic antibody against TNFα, e.g. SIMPONI®) in EDTA plasma and serum.

Tumor Necrosis Factor-alpha (TNFα) belongs to the proinflammatory cytokines, which promote and sustain inflammatory reactions. It is produced by macrophages and T cells and plays a central role in both acute and chronic inflammations. Consequently, antibodies against TNFa can treat chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, or psoriasis, as the antibodies directly target underlying inflammatory processes.

Typically, the clinical efficacy of an anti-TNFa therapy correlates with the trough level of the therapeutic antibody, or the drug level just before the next application of the anti-TNFa antibody. Several factors influence the trough level. Among them are dosage and frequency of anti-TNFa blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, or ADA).

It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFα antibody application.

The IDKmonitor® Golimumab Drug Level ELISA helps physicians monitor and optimize therapy early on. The IDKmonitor® Golimumab Drug Level ELISA is Health Canada Licensed.

Browse our other IDKmonitor® Golimumab ELISAs.